市場調査レポート

商品コード

1611201

非ステロイド性抗炎症薬の市場規模、シェア、動向分析レポート：適応疾患別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日: 2024年11月22日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 874,590円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,021,580円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,315,560円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

非ステロイド性抗炎症薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の非ステロイド性抗炎症薬市場規模は、2025～2030年にかけて5.66%のCAGRを記録し、2030年までに312億9,000万米ドルに達すると推定されています。

非ステロイド性抗炎症薬は、主に炎症や痛みを和らげ、体温上昇を下げるために使用される薬です。生理痛、頭痛、発熱、関節炎、捻挫、緊張、その他の慢性疼痛などの症状緩和を目的とした非ステロイド性抗炎症薬（NSAID）の配合率は高く、予測期間中の市場の牽引役となることが予想されます。

非ステロイド性抗炎症薬市場は、高齢者におけるこれらの疾患の有病率の高さと相まって、世界中で標的疾患や慢性疼痛の有病率が上昇しているなどの要因により、成長機会を目の当たりにすることが期待されます。さらに、OTC NSAIDsに対する需要の増加や、頭痛、片頭痛、月経痛に対するNSAIDsの採用が増加していることも、予測期間中の成長を後押しすると予想されます。

さらに、関節炎やその他の痛みに関連する疾患の有病率の増加も成長を支えるものと予想されます。例えば、変形性関節症の有病率は、欧州の他の国に比べて英国、フランス、ドイツで高いです。関節炎の有病率は、身体活動をよくする人ほど低く、その有病率は年齢とともに上昇すると見られています。したがって、関節炎の有病率の上昇も、予測期間中の成長に貢献すると期待されています。

主要な市場参入企業は、世界中で市場シェアを拡大するために、地理的拡大や非ステロイド性抗炎症薬の配合剤の採用などの戦略的イニシアチブを採用しています。例えば、Alkem LabsやDr.Reddy's Laboratories Ltdは、米国で非ステロイド性抗炎症薬を発売しています。さらに、疼痛管理やその他の炎症性疾患に対する市販薬の承認が増加していることも、予測期間中の成長を促進すると予想されます。このように、主要企業が採用する様々な戦略により、市場は成長を後押しする可能性が高いです。

さまざまな地域の政府は、片頭痛、関節炎、その他の疾患の負担を軽減するために、自国に有利な取り組みを行っています。例えば、米国国立衛生ラボ（National Institutes of Health）は、疼痛や炎症性疾患の管理を改善するための研究活動を加速させるためにHEALを開始しました。さらに、Patient-Centered Outcomes Research Instituteは、疼痛に対する非オピオイド治療の選択肢を導入するためのイニシアチブをとっています。こうした取り組みにより、予測期間中の成長拡大が期待されます。

非ステロイド性抗炎症薬市場レポートハイライト

2024年には、世界的に関節炎の有病率が高いことから、関節炎セグメントがNSAIDs市場を独占しました。
小売薬局セグメントが最大のシェアを占め、予測期間中もその優位性を維持すると予測されます。
アジア太平洋は、疼痛と関連疾患の有病率の高さ、患者数の多さ、地域全体の高齢者の増加などの要因により、予測期間中に大きなCAGRで成長すると予想されます。
北米は、関節炎の有病率の高さ、主要な市場参入企業の存在、地域内の研究活動の増加により、2024年の市場を独占しました。

地域ダッシュボード
市場規模と予測動向分析、2018～2030年
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- ノルウェー
- スウェーデン
- デンマーク
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第8章競合情勢

市場参入企業の分類
主要市場参入企業による最近の動向と影響分析
企業市場シェア分析、2024年
主要企業プロファイル
- Pfizer Inc.
- Bayer AG
- GSK plc
- Dr. Reddy's Laboratories Ltd
- Viatris Inc
- Teva Pharmaceutical Industries Ltd.
- Johnson And Johnson Services, Inc.
- Merck &Co., Inc.

図表

List of Tables

Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 4. North America NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 5. North America NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 6. North America NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 7. U.S. NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 8. U.S. NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 9. U.S. NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 10. Canada NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 11. Canada NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 12. Canada NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 13. Mexico NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 14. Mexico NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 15. Mexico NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 16. Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 17. Europe NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 18. Europe NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 19. Europe NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 20. UK NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 21. UK NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 22. UK NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 23. Germany NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 24. Germany NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 25. Germany NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 26. France NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 27. France NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 28. France NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 29. Spain NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 30. Spain NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 31. Spain NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 32. Italy NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 33. Italy NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 34. Italy NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 35. Denmark NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 36. Denmark NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 37. Denmark NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 38. Sweden NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 39. Sweden NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 40. Sweden NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 41. Norway NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 42. Norway NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 43. Norway NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 44. Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 45. Asia Pacific NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 46. Asia Pacific NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 47. Asia Pacific NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 48. Japan NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 49. Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 50. Japan NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 51. China NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 52. China NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 53. China NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 54. India NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 55. India NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 56. India NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 57. South Korea NSAIDs Market, By disease indication 2018 - 2030 (USD Million)
Table 58. South Korea NSAIDs Market, By route of administration 2018 - 2030 (USD Million)
Table 59. South Korea NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 60. Australia NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 61. Australia NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 62. Australia NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 63. Thailand NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 64. Thailand NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 65. Thailand NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 66. Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 67. Latin America NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 68. Latin America NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 69. Latin America NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 70. Brazil NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 71. Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 72. Brazil NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 73. Argentina NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 74. Argentina NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 75. Argentina NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 76. Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 77. Middle East & Africa NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 78. Middle East & Africa NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 79. Middle East & Africa NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 80. South Africa NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 81. South Africa NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 82. South Africa NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 83. Saudi Arabia NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 84. Saudi Arabia NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 85. Saudi Arabia NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 86. UAE NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 87. UAE NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 88. UAE NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
Table 89. Kuwait NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
Table 90. Kuwait NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
Table 91. Kuwait NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research approaches
Fig. 2 Value chain-based sizing & forecasting
Fig. 3 Market formulation & validation
Fig. 4 non-steroidal anti-inflammatory drugs market segmentation
Fig. 5 Market driver analysis (current & future impact)
Fig. 6 Market restraint analysis (current & future impact)
Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 8 Porter's five forces analysis
Fig. 9 NSAIDs market: Disease indication outlook and key takeaways
Fig. 10 NSAIDs market: Disease indication movement analysis
Fig. 11 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 12 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 13 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 14 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 15 NSAIDs market: Route of administration outlook and key takeaways
Fig. 16 NSAIDs market: Route of administration movement analysis
Fig. 17 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 NSAIDs market: Distribution channel outlook and key takeaways
Fig. 21 NSAIDs market: Distribution channel movement analysis
Fig. 22 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 North America non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 US non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Canada non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Mexico non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Europe non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 UK non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Germany non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 France non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Italy non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Spain non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Denmark non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Sweden non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Norway non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Asia Pacific non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Japan non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 China non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 India non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Australia non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Thailand non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 South Korea non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Latin America non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Brazil non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Argentina non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 MEA non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 South Africa non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Saudi Arabia non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 UAE non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Kuwait non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 List of key emerging company's/disruptors/innovators

Product Code: GVR-4-68039-952-5

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

The global non-steroidal anti-inflammatory drugs market size is estimated to reach USD 31.29 billion by 2030, registering a CAGR of 5.66% from 2025 to 2030, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.

The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy's Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.

Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

In 2024, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe
The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period
Asia Pacific region is expected to grow at a significant CAGR during the forecast period, owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region
North America dominated the market in 2024, due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Segment Definitions
- 1.2.1. Disease Indication
- 1.2.2. Route of Administration
- 1.2.3. Distribution Channel
- 1.2.4. Regional Scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights

Chapter 3. Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Rising Prevalence of Chronic Pain and Inflammatory Diseases
  - 3.2.1.2. Increase in geriatric population
  - 3.2.1.3. Awareness and Accessibility of OTC NSAIDs
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Side Effects
  - 3.2.2.2. Competition from Alternative Therapies
3.3. Non-Steroidal Anti-Inflammatory Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Bargaining power of suppliers
  - 3.3.1.2. Bargaining power of buyers
  - 3.3.1.3. Threat of substitutes
  - 3.3.1.4. Threat of new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic landscape
  - 3.3.2.3. Social landscape
  - 3.3.2.4. Technological landscape
  - 3.3.2.5. Environmental landscape
  - 3.3.2.6. Legal landscape

Chapter 4. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Movement Analysis
4.3. Non-Steroidal Anti-Inflammatory Drugs Market by Disease Indication (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Arthritis
- 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Migraine
- 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Ophthalmic Diseases
- 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Movement Analysis
5.3. Non-Steroidal Anti-Inflammatory Drugs Market by Route of Administration Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Oral
- 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Topical
- 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Others
- 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Movement Analysis
6.3. Non-Steroidal Anti-Inflammatory Drugs Market by Distribution Channel Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
6.5. Hospital Pharmacy
- 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Retail Pharmacy
- 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Online Pharmacy
- 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Non-Steroidal Anti-Inflammatory Drugs Market: Regional Estimates & Trend Analysis

7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Regulatory framework/ reimbursement structure
  - 7.3.3.3. Competitive scenario
  - 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
- 8.4.1. Pfizer Inc.
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Product benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Bayer AG
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. GSK plc
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. Dr. Reddy's Laboratories Ltd
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. Viatris Inc
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. Teva Pharmaceutical Industries Ltd.
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. Johnson And Johnson Services, Inc.
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. Merck & Co., Inc.
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product benchmarking
  - 8.4.8.4. Strategic initiatives

非ステロイド性抗炎症薬の市場規模、シェア、動向分析レポート：適応疾患別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

非ステロイド性抗炎症薬市場の成長と動向

非ステロイド性抗炎症薬市場レポートハイライト

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章非ステロイド性抗炎症薬市場の変数、動向、範囲

第4章非ステロイド性抗炎症薬市場：適応疾患別、推定・動向分析

第5章非ステロイド性抗炎症薬市場：投与経路別、推定・動向分析

第6章非ステロイド性抗炎症薬市場：流通チャネル別、推定・動向分析

第7章非ステロイド性抗炎症薬市場：地域別、推定・動向分析

第8章競合情勢

List of Tables

List of Figures

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

Chapter 4. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Estimates & Trend Analysis

Chapter 5. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Estimates & Trend Analysis

Chapter 6. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Non-Steroidal Anti-Inflammatory Drugs Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

非ステロイド性抗炎症薬の市場規模、シェア、動向分析レポート：適応疾患別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

非ステロイド性抗炎症薬市場の成長と動向

非ステロイド性抗炎症薬市場レポートハイライト

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 非ステロイド性抗炎症薬市場の変数、動向、範囲

第4章 非ステロイド性抗炎症薬市場：適応疾患別、推定・動向分析

第5章 非ステロイド性抗炎症薬市場：投与経路別、推定・動向分析

第6章 非ステロイド性抗炎症薬市場：流通チャネル別、推定・動向分析

第7章 非ステロイド性抗炎症薬市場：地域別、推定・動向分析

第8章 競合情勢

List of Tables

List of Figures

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

Chapter 4. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Estimates & Trend Analysis

Chapter 5. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Estimates & Trend Analysis

Chapter 6. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Non-Steroidal Anti-Inflammatory Drugs Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章非ステロイド性抗炎症薬市場の変数、動向、範囲

第4章非ステロイド性抗炎症薬市場：適応疾患別、推定・動向分析

第5章非ステロイド性抗炎症薬市場：投与経路別、推定・動向分析

第6章非ステロイド性抗炎症薬市場：流通チャネル別、推定・動向分析

第7章非ステロイド性抗炎症薬市場：地域別、推定・動向分析

第8章競合情勢